Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
NCT ID: NCT00151047
Last Updated: 2015-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
15 participants
INTERVENTIONAL
2003-03-31
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
NCT00258284
Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer
NCT01012141
Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
NCT00002775
Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients
NCT00714376
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
NCT02985021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Docetaxel and Capecitabine
Capecitabine
Docetaxel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Capecitabine
Docetaxel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Michigan Rogel Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maha Hussain, MD
Role: PRINCIPAL_INVESTIGATOR
The University of Michigan Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Wayne State University
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMCC 2-42
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.